Osteoclast differentiation and activation

被引：5187

作者：

Boyle, WJ ^{[2
]}

Simonet, WS

Lacey, DL

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] Prot Pathways Inc, Woodland Hills, CA 91367 USA

来源：

NATURE | 2003年 / 423卷 / 6937期

关键词：

D O I：

10.1038/nature01658

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Osteoclasts are specialized cells derived from the monocyte/macrophage haematopoietic lineage that develop and adhere to bone matrix, then secrete acid and lytic enzymes that degrade it in a specialized, extracellular compartment. Discovery of the RANK signalling pathway in the osteoclast has provided insight into the mechanisms of osteoclastogenesis and activation of bone resorption, and how hormonal signals impact bone structure and mass. Further study of this pathway is providing the molecular basis for developing therapeutics to treat osteoporosis and other diseases of bone loss.

引用

收藏

页码：337 / 342

页数：6

相关论文

共 77 条

[21] Regulation of receptor activator of NF-κB ligand-induced osteoclastogenesis by endogenous interferon-β (INF-β) and suppressors of cytokine signaling (SOCS) -: The possible counteracting role of SOCSs in IFN-β-inhibited osteoclast formation [J].

Hayashi, T ;

Kaneda, T ;

Toyama, Y ;

Kumegawa, M ;

Hakeda, Y .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :27880-27886

[22] The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption [J].

Hofbauer, LC ;

Khosla, S ;

Dunstan, CR ;

Lacey, DL ;

Boyle, WJ ;

Riggs, BL .

JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (01) :2-12

[23] U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells [J].

Hotokezaka, H ;

Sakai, E ;

Kanaoka, K ;

Saito, K ;

Matsuo, K ;

Kitaura, H ;

Yoshida, N ;

Nakayama, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (49) :47366-47372

[24] Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand [J].

Hsu, HL ;

Lacey, DL ;

Dunstan, CR ;

Solovyev, I ;

Colombero, A ;

Timms, E ;

Tan, HL ;

Elliott, G ;

Kelley, MJ ;

Sarosi, I ;

Wang, L ;

Xia, XZ ;

Elliott, R ;

Chiu, L ;

Black, T ;

Scully, S ;

Capparelli, C ;

Morony, S ;

Shimamoto, G ;

Bass, MB ;

Boyle, WJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3540-3545

[25] Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis [J].

Hughes, AE ;

Ralston, SH ;

Marken, J ;

Bell, C ;

MacPherson, H ;

Wallace, RGH ;

van Hul, W ;

Whyte, MP ;

Nakatsuka, K ;

Hovy, L ;

Anderson, DM .

NATURE GENETICS, 2000, 24 (01) :45-48

[26] Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator [J].

Ishida, N ;

Hayashi, K ;

Hoshijima, M ;

Ogawa, T ;

Koga, S ;

Miyatake, Y ;

Kumegawa, M ;

Kimura, T ;

Takeya, T .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (43) :41147-41156

[27]

Jimi E, 1999, J IMMUNOL, V163, P434

[28] NF-κB in cancer:: From innocent bystander to major culprit [J].

Karin, M ;

Cao, YX ;

Greten, FR ;

Li, ZW .

NATURE REVIEWS CANCER, 2002, 2 (04) :301-310

[29] Minireview: The OPG/RANKL/RANK system [J].

Khosla, S .

ENDOCRINOLOGY, 2001, 142 (12) :5050-5055

[30] Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression [J].

Kim, YH ;

Kim, GS ;

Baek, JH .

EXPERIMENTAL AND MOLECULAR MEDICINE, 2002, 34 (02) :145-151

← 1 2 3 4 5 6 7 8 →